

Emplicure initiates clinical study in collaboration with a leading CRO

Emplicure AB (publ) announces today that the company, through its subsidiary Amplicon, initiates a collaboration on a clinical study with CTC Clinical Trial Consultants AB, a recognized contract research organization (CRO) with extensive experience in the nicotine field.

The clinical study is an exploratory pharmacokinetic phase I study with the Ampli01 nicotine pouch. The purpose of the study is to investigate the uptake and release of nicotine from the company's unique and innovative bioceramic technology and also to study pharmacodynamics and safety.

"We look forward to working with CTC to conduct this study and to ensure the highest quality and reliability. This study is a milestone for Amplicon and demonstrates our commitment to advancing research in the field of tobacco-free nicotine delivery and improving the quality of life for those seeking alternatives to traditional smoking," said Håkan Engqvist, CEO of Emplicure AB.

"We are very pleased and enthusiastic about starting the collaboration with the Uppsala-based company Emplicure. We have extensive experience in the field of clinical development of tobacco-free products", says Anders Millerhofv, CEO of Clinical Trial Consultants AB.

For more information, please contact:

Håkan Engqvist

CEO

Tel: +46 (0)702 569 500

Email: hakan.engqvist@emplicure.com

Erik Magnusson

CFO

Tel: +46 (0)70 856 52 45

Email: erik.magnusson@emplicure.com

Certified Adviser

Emplicure's Certified Adviser is Erik Penser Bank.



Emplicure uses patented bioceramic technology to develop innovative and effective products to help consumers and patients live better lives. Our consumer division makes tiny, long-lasting and flavorful nicotine pouches that can be an alternative to smoking. Our pharmaceutical division develops safer and tamper-resistant treatments for pain. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com